Lifestyle Factors | Hormone Replacement Therapy
For a copy of these publications and others related to the NIH-AARP Diet and Health Study, visit the National Cancer Institute.
Lifetime Weight History and Endometrial Cancer Risk by Type of Menopausal Hormone Use in the NIH-AARP Diet and Health Study
Current adiposity and adult weight gain in women are associated with substantial increases in the risk of endometrial cancer. The association is particularly evident among never users of menopausal hormone therapy, according to findings from the National Institutes of Health-AARP Diet and Health Study. In a five-year following up of 103,882 women ages 50-71, 677 cases of endometrial cancer developed.
- High body mass index (BMI) at baseline and adult weight gain were associated with increased endometrial cancer risk.
- Consistent overweight or obesity during adult hood was associated with greater risk of endometrial cancer than being overweight or obese only in later adult life.
- Menopausal hormone therapy was independently associated with increased risk of endometrial cancer.
- The relationship between both BMI and adult weight gain and endometrial cancer risk were stronger among nonusers than among current or former users of menopausal hormones.
This investigation of the relationship between estrogen therapy – by itself or in combination with progestin – and the risk of developing ovarian cancer finds that the degree of risk depends on the duration of use.
Further information about the study or individual reports may be obtained by contacting Nancy Wood of AARP at firstname.lastname@example.org or 202-434-2583.